Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

LRRK2 Pathways Leading to Neurodegeneration
Mark Cookson
Current Neurology and Neuroscience Reports (2015) Vol. 15, Iss. 7
Open Access | Times Cited: 133

Showing 26-50 of 133 citing articles:

GTP binding regulates cellular localization of Parkinson's disease-associated LRRK2
Marian Blanca Ramírez, Antonio Jesús Lara Ordóñez, Elena Fdez, et al.
Human Molecular Genetics (2017) Vol. 26, Iss. 14, pp. 2747-2767
Open Access | Times Cited: 73
Models of LRRK2-Associated Parkinson’s Disease
Yulan Xiong, Ted M. Dawson, Valina L. Dawson
Advances in neurobiology (2017), pp. 163-191
Open Access | Times Cited: 71
LRRK2 kinase plays a critical role in manganese-induced inflammation and apoptosis in microglia
Judong Kim, Edward Pajarillo, Asha Rizor, et al.
PLoS ONE (2019) Vol. 14, Iss. 1, pp. e0210248-e0210248
Open Access | Times Cited: 71
LRRK2 mediates microglial neurotoxicity via NFATc2 in rodent models of synucleinopathies
Changyoun Kim, A Beilina, Nathan Smith, et al.
Science Translational Medicine (2020) Vol. 12, Iss. 565
Open Access | Times Cited: 64
Targeting the Autophagy/Lysosomal Degradation Pathway in Parkinsons Disease
Pilar Rivero-Ríos, Jesús Madero‐Pérez, Belén Fernández, et al.
Current Neuropharmacology (2016) Vol. 14, Iss. 3, pp. 238-249
Open Access | Times Cited: 61
The development of inhibitors of leucine‐rich repeat kinase 2 (LRRK2) as a therapeutic strategy for Parkinson's disease: the current state of play
Sonia Azeggagh, Daniel C. Berwick
British Journal of Pharmacology (2021) Vol. 179, Iss. 8, pp. 1478-1495
Open Access | Times Cited: 46
Doubly Constrained C-terminal of Roc (COR) Domain-Derived Peptides Inhibit Leucine-Rich Repeat Kinase 2 (LRRK2) Dimerization
Pragya Pathak, Krista K. Alexander, Leah G. Helton, et al.
ACS Chemical Neuroscience (2023) Vol. 14, Iss. 11, pp. 1971-1980
Open Access | Times Cited: 17
Understanding role of pesticides in development of Parkinson's disease: Insights from Drosophila and rodent models
Saba Afsheen, Ahmed Shaney Rehman, Azfar Jamal, et al.
Ageing Research Reviews (2024) Vol. 98, pp. 102340-102340
Closed Access | Times Cited: 7
Proteomic analysis reveals co-ordinated alterations in protein synthesis and degradation pathways in LRRK2 knockout mice
Laura Pellegrini, David N. Hauser, Yan Li, et al.
Human Molecular Genetics (2018) Vol. 27, Iss. 18, pp. 3257-3271
Open Access | Times Cited: 55
Are rodent models of Parkinson’s disease behaving as they should?
Siv Vingill, Natalie Connor‐Robson, Richard Wade‐Martins
Behavioural Brain Research (2017) Vol. 352, pp. 133-141
Closed Access | Times Cited: 54
Cryo-EM analysis of homodimeric full-length LRRK2 and LRRK1 protein complexes
Kushal Sejwal, Mohamed Chami, Hervé Remigy, et al.
Scientific Reports (2017) Vol. 7, Iss. 1
Open Access | Times Cited: 53
Lrrk promotes tau neurotoxicity through dysregulation of actin and mitochondrial dynamics
Farah H. Bardai, Dalila G. Ordonez, Rachel M. Bailey, et al.
PLoS Biology (2018) Vol. 16, Iss. 12, pp. e2006265-e2006265
Open Access | Times Cited: 53
Lovastatin protects neurite degeneration inLRRK2-G2019Sparkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3β activity
Chin‐Hsien Lin, Han-I Lin, Meng‐Ling Chen, et al.
Human Molecular Genetics (2016) Vol. 25, Iss. 10, pp. 1965-1978
Open Access | Times Cited: 51
Higher urate in LRRK2 mutation carriers resistant to Parkinson disease
Rachit Bakshi, Eric A. Macklin, Robert Logan, et al.
Annals of Neurology (2019) Vol. 85, Iss. 4, pp. 593-599
Closed Access | Times Cited: 51
P62/SQSTM1 is a novel leucine-rich repeat kinase 2 (LRRK2) substrate that enhances neuronal toxicity
Alexia F. Kalogeropulou, Jing Zhao, Marc Bolliger, et al.
Biochemical Journal (2018) Vol. 475, Iss. 7, pp. 1271-1293
Open Access | Times Cited: 50
Recent Developments in LRRK2-Targeted Therapy for Parkinson’s Disease
Ye Zhao, Nicolas Dzamko
Drugs (2019) Vol. 79, Iss. 10, pp. 1037-1051
Closed Access | Times Cited: 50
Divergent Effects of G2019S and R1441C LRRK2 Mutations on LRRK2 and Rab10 Phosphorylations in Mouse Tissues
Lucia Iannotta, Alice Biosa, Jillian H. Kluss, et al.
Cells (2020) Vol. 9, Iss. 11, pp. 2344-2344
Open Access | Times Cited: 45
Clinically Precedented Protein Kinases: Rationale for Their Use in Neurodegenerative Disease
Caroline Benn, Lee A. Dawson
Frontiers in Aging Neuroscience (2020) Vol. 12
Open Access | Times Cited: 42
Genotype-driven therapeutic developments in Parkinson’s disease
Jannik Prasuhn, Norbert Brüggemann
Molecular Medicine (2021) Vol. 27, Iss. 1
Open Access | Times Cited: 33
Parkinson’s Disease Subtyping Using Clinical Features and Biomarkers: Literature Review and Preliminary Study of Subtype Clustering
Seung Hyun Lee, Sang‐Min Park, Sang Seok Yeo, et al.
Diagnostics (2022) Vol. 12, Iss. 1, pp. 112-112
Open Access | Times Cited: 25
LRRK2 mutant knock-in mouse models: therapeutic relevance in Parkinson's disease
Eunice Eun Seo Chang, Philip Wing‐Lok Ho, Huifang Liu, et al.
Translational Neurodegeneration (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 23
Recombinant Antibody Fragments for Immunotherapy of Parkinson’s Disease
Karen Manoutcharian, Goar Gevorkian
BioDrugs (2024) Vol. 38, Iss. 2, pp. 249-257
Open Access | Times Cited: 5
A proteomic analysis of LRRK2 binding partners reveals interactions with multiple signaling components of the WNT/PCP pathway
Alena Salašová, Chika Yokota, David Potěšil, et al.
Molecular Neurodegeneration (2017) Vol. 12, Iss. 1
Open Access | Times Cited: 48
Comparative Protein Interaction Network Analysis Identifies Shared and Distinct Functions for the Human ROCO Proteins
James E. Tomkins, Sybille Dihanich, Alexandra Beilina, et al.
PROTEOMICS (2018) Vol. 18, Iss. 10
Open Access | Times Cited: 44
Recombinant Antibody Fragments for Neurodegenerative Diseases
Karen Manoutcharian, Roxanna Pérez-Garmendia, Goar Gevorkian
Current Neuropharmacology (2016) Vol. 15, Iss. 5
Open Access | Times Cited: 41

Scroll to top